Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone.
We investigated the possible association between genetic polymorphisms in the dopamine receptor and serotonin transporter genes and the responses of schizophrenic patients treated with either risperidone or perospirone. The subjects comprised 27 patients with schizophrenia who were clinically evaluated both before and after treatment. The genotyping of the polymorphisms of the dopamine D2 receptor gene (DRD2) (rs1801028 and rs6277), the dopamine D4 receptor gene (DRD4) (120-bp tandem repeats and rs1800955), and serotonin transporter gene (5HTT)(variable number of tandem repeats; VNTR) were performed using the real-time polymerase chain reaction and sequencing. In DRD2 and 5HTT-VNTR, there were no significant correlations between clinical response and polymorphism in the case of risperidone, and for perospirone treatment it was impossible to analyze the clinical evaluation due to the absence of genotype information. On the other hand, in DRD4 there were significant correlations in the two-factor interaction effect on the Positive and Negative Syndrome Scale (PANSS) between the two drugs [120-bp tandem repeat, p=0.003; rs1800955, p=0.043]. Although the small sample represents a serious limitation, these results suggest that variants in DRD4 are a predictor of whether treatment will be more effective with risperidone or with perospirone in individual patients.
Tsutsumi
Atsushi
A
Department of Neuropsychiatry, Osaka Medical College, Takatsuki, Osaka, Japan.
Kanazawa
Tetsufumi
T
Kikuyama
Hiroki
H
Okugawa
Gaku
G
Uenishi
Hiroyuki
H
Miyamoto
Toshio
T
Matsumoto
Naoki
N
Koh
Jun
J
Shinosaki
Kazuhiro
K
Kishimoto
Toshifumi
T
Yoneda
Hiroshi
H
Kinoshita
Toshihiko
T